Pemafibrate - Kowa Pharmaceutical
Alternative Names: K 877; K-808; K-877 CR; K-877 IR; K-877-BC; K-877-ER; K-877-FL; ParmodiaLatest Information Update: 14 Aug 2024
At a glance
- Originator Kowa Pharmaceutical
- Developer Jaeb Center for Health Research; Kowa Pharmaceutical
- Class Antihyperlipidaemics; Benzoxazoles; Butyric acids; Eye disorder therapies; Fibric acid derivatives; Hepatoprotectants; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperlipidaemia
- Preregistration Dyslipidaemias
- Phase III Diabetic retinopathy; Hypercholesterolaemia; Hypertriglyceridaemia
- Phase II Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary biliary cirrhosis
Most Recent Events
- 14 Aug 2024 Kowa Research Institute plans a phase I trial for in Primary biliary cirrhosis in August 2024 (NCT06525311)
- 26 Jan 2024 Phase-II clinical trials in Primary biliary cirrhosis (Treatment-experienced) in USA (PO) (NCT06247735) .
- 01 Oct 2023 Phase-II clinical trials in Primary biliary cirrhosis in Japan (PO) (Kowa Pharmaceuticals pipeline, October 2023)